Literature DB >> 22200619

The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children.

Yoichi Tanaka1, Atsushi Manabe, Hisaya Nakadate, Kensuke Kondoh, Kozue Nakamura, Katsuyoshi Koh, Tomoyuki Utano, Akira Kikuchi, Takako Komiyama.   

Abstract

The association between inosine triphosphate pyrophosphatase (ITPA) activity and toxicity of 6-mercaptopurine (6-MP) was retrospectively evaluated in 65 Japanese children with acute lymphoblastic leukemia (ALL). Patients with an ITPA activity of less than 126 μmol/h/gHb presented with hepatotoxicity more frequently than those with higher ITPA activity (p<0.01). The average 6-MP dose during maintenance therapy administered to two patients with the ITPA deficiency was lower than that given to the other patients. Measuring ITPA activity is important for ensuring the safety of maintenance therapy for Asians with ALL because thiopurine S-methyl transferase mutations are rare in the Asian population. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22200619     DOI: 10.1016/j.leukres.2011.11.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

1.  NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia.

Authors:  Kanhatai Chiengthong; Chupong Ittiwut; Sasipa Muensri; Jiratchaya Sophonphan; Darintr Sosothikul; Panya Seksan; Koramit Suppipat; Kanya Suphapeetiporn; Vorasuk Shotelersuk
Journal:  Haematologica       Date:  2015-09-24       Impact factor: 9.941

Review 2.  Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.

Authors:  Rochelle R Maxwell; Peter D Cole
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

3.  Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.

Authors:  Y Tanaka; A Manabe; H Fukushima; R Suzuki; H Nakadate; K Kondoh; K Nakamura; K Koh; T Fukushima; M Tsuchida; K Koike; N Kiyokawa; E Noguchi; R Sumazaki; T Komiyama
Journal:  Pharmacogenomics J       Date:  2014-11-18       Impact factor: 3.550

4.  NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine.

Authors:  Nicholas C K Valerie; Anna Hagenkort; Brent D G Page; Geoffrey Masuyer; Daniel Rehling; Megan Carter; Luka Bevc; Patrick Herr; Evert Homan; Nina G Sheppard; Pål Stenmark; Ann-Sofie Jemth; Thomas Helleday
Journal:  Cancer Res       Date:  2016-08-16       Impact factor: 12.701

5.  Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.

Authors:  Y Tanaka; H Nakadate; K Kondoh; K Nakamura; K Koh; A Manabe
Journal:  Pharmacogenomics J       Date:  2017-04-18       Impact factor: 3.550

6.  Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants.

Authors:  Der-Shiun Wang; Chih-Hsiang Yu; Chien-Yu Lin; Ya-Hsuan Chang; Kai-Hsin Lin; Dong-Tsamn Lin; Shiann-Tarng Jou; Meng-Yao Lu; Hsiu-Hao Chang; Shu-Wha Lin; Hsuan-Yu Chen; Yung-Li Yang
Journal:  Pediatr Res       Date:  2020-03-27       Impact factor: 3.756

7.  Genetic Polymorphisms of Drug-Metabolizing Enzymes Involved in 6-Mercaptopurine-Induced Myelosuppression in Thai Pediatric Acute Lymphoblastic Leukemia Patients.

Authors:  Kanyarat Khaeso; Nontaya Nakkam; Patcharee Komwilaisak; Piyathida Wongmast; Su-On Chainansamit; Areerat Dornsena; Sirimas Kanjanawart; Suda Vannaprasaht; Wichittra Tassaneeyakul
Journal:  J Pediatr Genet       Date:  2020-09-08

Review 8.  Effect of ITPA Polymorphism on Adverse Drug Reactions of 6-Mercaptopurine in Pediatric Patients with Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.

Authors:  Yeonhong Lee; Eun Jeong Jang; Ha-Young Yoon; Jeong Yee; Hye-Sun Gwak
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-29

9.  Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia.

Authors:  Gabriele Stocco; Raffaella Franca; Federico Verzegnassi; Margherita Londero; Marco Rabusin; Giuliana Decorti
Journal:  Front Genet       Date:  2013-01-07       Impact factor: 4.599

Review 10.  Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.

Authors:  Kjeld Schmiegelow; Stine N Nielsen; Thomas L Frandsen; Jacob Nersting
Journal:  J Pediatr Hematol Oncol       Date:  2014-10       Impact factor: 1.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.